Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Sixteen RNAi-Related Patent Applications

Premium
Title: Polynucleotides for Causing RNA Interference and Method for Inhibiting Gene Expression Using the Same
 
Number: 20080113351
 
Filed: Nov. 13, 2006
 
Lead Inventor: Yuki Naito, AlphaGen
 
The invention, the patent application’s abstract states, “provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to [certain] rules … is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.”
 
The abstract notes that the sequence segment is designed so that “the 3' end base is adenine, thymine, or uracil, the 5' end base is guanine or cytosine, a 7-base sequence from the 3' end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and the number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.”
 

 
Title: siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2
 
Number: 20080113369
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.”
 

 
Title: siRNA Targeting Apolipoprotein B
 
Number: 20080113370
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for apoB.”
 

 
Title: siRNA Targeting Beta Secretase
 
Number: 20080113371
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.”
 

 
Title: siRNA Targeting Glucagon Receptor
 
Number: 20080113372
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR.”
 

 
Title: siRNA Targeting Amyloid Beta Precursor Protein
 
Number: 20080113373
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.”
 

 
Title: siRNA Targeting Fructose-1,6-Biphosphatase
 
Number: 20080113374
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1.”
 

 
Title: siRNA Targeting Superoxide Dismutase 1
 
Number: 20080113375
 
Filed: Oct. 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1.”
 

 
Title: siRNA Targeting Myeloid Differentiation Primary Response Gene
 
Number: 20080113376
 
Filed: Oct. 30, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD1.”
 

 
Title: siRNA Targeting Proto-Oncogene MET
 
Number: 20080113377
 
Filed: Oct. 30, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for proto-oncogene MET.”
 

 
Title: siRNA Targeting Interleukin-1 Receptor-Associated Kinase 4
 
Number: 20080113378
 
Filed: Oct. 30, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.”
 

 
Title: Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
 
Number: 20080113930
 
Filed: May 10, 2007
 
Lead Inventor: Pamela Tan, Alnylam Europe (Alnylam Pharmaceuticals)
 
According to the patent application’s abstract, “the invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the PCSK9 gene comprising an antisense strand having a nucleotide sequence [that] is less that 30 nucleotides in length … [and] substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, [as well as] methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition.”
 

 
Title: RNAi Modulation of Aha and Therapeutic Uses Thereof
 
Number: 20080113931
 
Filed: May 18, 2007
 
Lead Inventor: Rainer Constien, Alnylam Europe (Alnylam Pharmaceuticals)
 
The invention, the patent application’s abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of an Aha gene comprising an antisense strand having a nucleotide sequence [that] is less that 30 nucleotides in length … [and] substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition, and methods for inhibiting the expression of an Aha gene in a cell.”
 

 
Title: Functional and Hyperfunctional siRNA Directed Against Bcl-2
 
Number: 20080114162
 
Filed: Oct. 16, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing Bcl-2.”
 

 
Title: Transdermal Delivery System for Polynucleotides
 
Number: 20080114281
 
Filed: Jan. 25, 2005 PCT Filed: Jan. 25, 2005
 
Lead Inventor: James Birchall, Transpharma Medical
 
According to the patent application’s abstract, the invention “relates to a system for intradermal or transdermal delivery of oligonucleotides or polynucleotides, and to methods of use thereof. Particularly, the … invention relates to a system comprising an apparatus that generates micro-channels in the skin of a subject in conjunction with a pharmaceutical composition comprising an oligonucleotide or polynucleotide, wherein the oligonucleotide or polynucleotide can be delivered into the organism through the micro-channels. The system and methods of the … invention achieve expression of target proteins encoded by the polynucleotides, and hence are useful in immunization and gene therapy.”
 

 
Title: Maize microRNA Sequences       
 
Number: 20080115240
 
Filed: Oct. 5, 2007
 
Lead Inventor: Milo Aukerman, DuPont de Nemours
 
The patent application, its abstract states, claims “methods and compositions useful in target sequence suppression and target sequence validation. … Polynucleotide constructs useful for gene silencing, as well as cells, plants and seeds comprising the polynucleotides and a method for using microRNAs to silence a target sequence are also described.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.